Synergy Pharmaceuticals
New York
About Synergy Pharmaceuticals
Synergy Pharmaceuticals Inc., headquartered in New York, NY with laboratories in Doylestown, PA, is a biopharmaceutical company focused on the research and development of novel therapies for the treatment of chronic idiopathic constipation, irritable bowel syndrome with constipation and other difficult-to-treat gastrointestinal (GI) conditions. Synergy’s lead drug, plecanatide, and next-generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate cyclase-C (“GC-C”) agonists.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $10K – $50K
- Total funding: $407.2M
- Funding stage: IPO
- Last round: Post-IPO Debt (Sep 2017)
- Ticker: nasdaq:SGYP
- Website: synergypharma.com
- Phone: 212-297-0020
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/synergy-pharmaceuticals-208549 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.